<DOC>
	<DOCNO>NCT02369211</DOCNO>
	<brief_summary>To examine pharmacoeconomics IV acetaminophen ( Ofirmev ) . Specifically , examine potential improve hospital efficiency patient outcomes . The investigator compare addition IV acetaminophen versus placebo postoperative PACU recovery time , inpatient hospital length stay ( LOS ) , patient satisfaction score , postoperative pain score , consumption opiate rescue agent side effect , cost associate postoperative medication among patient undergo robotic-assisted laparoscopic prostatectomy ( RALP ) .</brief_summary>
	<brief_title>Pharmacoeconomics Related Patient Outcomes Multi-dose Intravenous Acetaminophen ( OFIRMEV )</brief_title>
	<detailed_description />
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Patients undergo roboticassisted laparoscopic prostatectomy â‰¥18 year old male ASA class 14 Chronic opiate use Liver disease ( know history hepatitis B C , cirrhosis , nonalcoholic steatohepatitis , history alcoholism , ALT/AST great 3 time upper limit normal past 3 month ) Allergy/hypersensitivity acetaminophen Patients baseline dementia Chronic diathesis Chronic kidney disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acetaminophen</keyword>
</DOC>